Zoetis Launches DRAXXIN 25 to Treat Small Calves for BRD
Make sure you
never miss a post.
SUBSCRIBE NOW

Zoetis Launches DRAXXIN 25 to Treat Small Calves for BRD

January 21, 2015
POSTED BY: Greg Edwards | DVM | Managing Veterinarian | Dairy Technical Services | Zoetis

Zoetis today announced the launch of DRAXXIN® 25 (tulathromycin injection) Injectable Solution, a lower concentration of DRAXXIN® (tulathromycin) Injectable Solution, to treat bovine respiratory disease (BRD) in suckling, dairy and veal calves.

Just like the current concentration of DRAXXIN, DRAXXIN 25 offers broad-spectrum coverage against the major causes of BRD, including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. However, producers and veterinarians should note that DRAXXIN 25 has a pre-slaughter withdrawal time of 22 days, compared with the 18-day pre-slaughter time for DRAXXIN.

“The efficacy of DRAXXIN has made it a leading choice by veterinarians and producers for the treatment of BRD in larger, ruminating calves,” said Dr. Robert Lynch, senior veterinarian, Dairy Technical Services, Zoetis. “The new formulation of DRAXXIN 25 allows for more-accurate and convenient dosing for smaller calves. Producers and veterinarians can be confident they are administering the correct treatment needed.”

 

PRODUCT

INDICATIONS

APPROVED DOSAGE

LABELED TREATMENT/ ROUTE OF ADMINISTRATION

PRE-SLAUGHTER WITHDRAWAL

DRAXXIN® 25

Treatment of BRD

1 mL/22 lb.

(Do not administer more than 11.5 mL

per injection site.)

Single dose,

subcutaneous

22 days

DRAXXIN

Treatment and control of BRD, treatment of pinkeye

1.1 mL/100 lb.

(Do not administer more than 10 mL per injection site.)

Single dose,

subcutaneous

18 days

 

DRX-00029

COMMENTS

Have a Comment? Subscribe